SEC Comment Letter for NRX Pharmaceuticals, (NRXP) — Apr 15, 2022
NRX Pharmaceuticals, Inc.
Date: April 15, 2022 · CIK: 0001719406 · Accession: 0000000000-22-004081
AI Filing Summary & Sentiment
File numbers found in text: 333-264201
Letter
United States securities and exchange commission logo April 15, 2022 Alessandra Daigneault, Esq. General Counsel and Secretary NRX Pharmaceuticals, Inc. 1201 North Market Street, Suite 111 Wilmington, Delaware 19801 Re:NRX Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed April 8, 2022 File No. 333-264201 Dear Ms. Daigneault: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Abby Adams at (202) 551-6902 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Alexander Lloyd, Esq.
Show Raw Text
United States securities and exchange commission logo
April 15, 2022
Alessandra Daigneault, Esq.
General Counsel and Secretary
NRX Pharmaceuticals, Inc.
1201 North Market Street, Suite 111
Wilmington, Delaware 19801
Re:NRX Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed April 8, 2022
File No. 333-264201
Dear Ms. Daigneault:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Abby Adams at (202) 551-6902 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Alexander Lloyd, Esq.